Nasus Pharma Ltd.
NSRX | AMEX
$3.16
-$0.15 (-4.53%)
At close: Oct 30, 2026, 3:59 PM ET
$3.16
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 3:59 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | -2.97K | -2.97K | -1.39M | n/a | -626 | -626 | -330.50 | -330.50 | -435.50 | -435.50 | -418.50 | -418.50 | -107 | -107 |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 256.50 | 256.50 | n/a | n/a | 75 | 75 | n/a | n/a | n/a | n/a | 7 | 7 | 12.50 | 12.50 |
Other Working Capital | -24.71K | -37.50 | -245.41K | n/a | 73.98K | 133 | 45.50 | 45.50 | 159.50 | 159.50 | 81 | 81 | 60.50 | 60.50 |
Other Non-Cash Items | -1.8M | -266 | 230.69K | n/a | -197.48K | 201.50 | 40 | 40 | 183.50 | 183.50 | 54.50 | 54.50 | -204.50 | -204.50 |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -183.82K | -37.50 | -203.07K | n/a | 77.6K | 133 | 45.50 | 45.50 | 159.50 | 159.50 | 81 | 81 | 60.50 | 60.50 |
Operating Cash Flow | -1.99M | -3.02K | -1.37M | n/a | -120.43K | -216.50 | -242.50 | -242.50 | -90 | -90 | -276 | -276 | -238.50 | -238.50 |
Capital Expenditures | -1.32K | n/a | -4.23K | n/a | 3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | -907.01K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -314.61K | -477.50 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -314.61K | -477.50 | -911.24K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | 31.39K | n/a | 100.13K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | 6.8K | n/a | n/a | n/a | 180 | -55.50 | -55.50 | 440.50 | 440.50 | n/a | n/a | 527.50 | 527.50 |
Financial Cash Flow | 4.48M | 6.8K | 2.6M | n/a | 100.13K | 180 | -55.50 | -55.50 | 440.50 | 440.50 | n/a | n/a | 527.50 | 527.50 |
Net Cash Flow | 2.25M | n/a | 336.18K | -232 | 68.89K | n/a | n/a | -916 | 916 | n/a | n/a | -751 | 751 | n/a |
Free Cash Flow | -1.99M | -3.02K | -1.37M | n/a | -120.43K | -216.50 | -242.50 | -242.50 | -90 | -90 | -276 | -276 | -238.50 | -238.50 |
Adj. Free Cash Flow | -1.99M | -3.28K | -1.37M | n/a | -120.51K | -291.50 | -242.50 | -242.50 | -90 | -90 | -283 | -283 | -251 | -251 |
Maintenance CapEx | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Growth CapEx | -1.32K | n/a | -4.23K | n/a | 3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Owner Earnings | -1.99M | -3.02K | -1.37M | n/a | -120.43K | -216.50 | -242.50 | -242.50 | -90 | -90 | -276 | -276 | -238.50 | -238.50 |
Add to Watchlist
Select watchlists to add or remove NSRX